710 Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist)

• Jeffrey Schlom,
• Claudia Palena,
• Kristen Fousek,
• Lucas Horn,
• Haiyan Qin,
• Bobby Reddy,
• Lennie Sender,
• Patrick Soon Shiong

Affiliations

Jeffrey Schlom

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Claudia Palena

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

Kristen Fousek

Aff1 grid.39382.33000000012160926XBaylor College of Medicine Houston TX USA

Lucas Horn

1National Cancer Institute, Bethesda, MD, USA

Haiyan Qin

Department of Health Management, Shenzhen People`s Hospital, Second Clinical Medical College of Jinan University, First affiliated Hospital of South University of Science and Technology, Shenzhen, China

Bobby Reddy

2ImmunityBio, Inc., Culver City, CA, United States

Lennie Sender

2ImmunityBio, Inc., Culver City, CA, United States

Patrick Soon Shiong

2ImmunityBio, Inc., Culver City, CA, United States